Genomic/Proteomic PTB Network: UAB Clinical Core Center

基因组/蛋白质组 PTB 网络：UAB 临床核心中心

• 批准号: 7767765
• 负责人: Joseph Ramon Biggio
• 金额: $ 18.3万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2013-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7767765
• 关键词: Adherence; Area; Clinical; Clinical Research; Clinical Trials Design; Functional disorder; Funding; Genomics; Institution; Intervention; Leadership; Modeling; Morbidity - disease rate; National Institute of Child Health and Human Development; Patients; Performance; Perinatal; Positioning Attribute; Premature Birth; Prevention; Productivity; Proteomics; Protocols documentation; Publications; Ramp; Research; Research Design; Research Infrastructure; Research Personnel; Role; Testing; Women' s Health; base; data acquisition; effective intervention; fetal medicine; improved; member; mortality; prevent; prospective; protocol development; randomized trial; research facility; success

Preterm birth remains the leading cause of perinatal morbidity and mortality, the rate of preterm birth continues to increase, and effective interventions to prevent preterm birth remain illusive. Investigators in the Center for Research in Women's Health at our institution have provided strong clinical research leadership in this area for 25 years. We have successfully acquired millions of dollars in federal funding to conduct clinical studies designed to improve our understanding of the pathophysiology of preterm birth as well as to test many potential interventions in prospective randomized trials. The productivity of our group has resulted in hundreds of publications in the area of preterm birth and its prevention. Our excellence in performing high- quality well-designed clinical trials is widely known. Germane to this application is our particular strength and success in performing multi-center trials and providing a leadership role in research networks including the NICHD Maternal-Fetal Medicine Units Network in which we have been a participating institution for nearly 15 years. Indeed, UAB was ranked first in overall performance among the 14 centers in this Network in the most recent objective ranking of member institutions. Thus, we believe that we are particularly well- positioned, not only to effectively participate, but also to provide leadership as a Clinical Core Center in the proposed Genomic and Proteomic Network. In this application, we will describe in detail our extremely successful clinical research facilities and infrastructure. We will also emphasize our well-documented strengths including patient accrual and retention, high-quality data acquisition and entry, rapid ramp-up to initiate new trials, protocol adherence, analysis and publication productivity, and collaborative success in protocol development and implementation in the NICHD MFMU Network which appears to be a model upon which the proposed new network is based. We believe that our enthusiasm and commitment to this project will be evident and we believe that our qualifications will be very competative for consideration.

早产仍然是围产期发病率和死亡率的主要原因，早产率 持续增加，预防早产的有效干预措施仍然遥不可及。调查人员在 我们机构的妇女健康研究中心在以下方面提供了强大的临床研究领导力 这个领域已经有25年了。我们已成功获得数百万美元的联邦资金来进行临床 旨在提高我们对早产病理生理学的理解并测试 前瞻性随机试验中有许多潜在的干预措施。我们团队的生产力导致了 数百份有关早产及其预防的出版物。我们在高绩效方面的卓越表现 精心设计的高质量临床试验是众所周知的。对此应用的密切关注是我们的独特优势 成功进行多中心试验并在研究网络中发挥领导作用，包括 NICHD 母胎医学中心网络，我们已成为近 15 个参与机构 年。事实上，UAB 的整体表现在该网络的 14 个中心中排名第一。 成员机构的最新客观排名。因此，我们相信我们特别好—— 不仅能够有效参与，而且能够作为临床核心中心发挥领导作用 提出的基因组和蛋白质组网络。在此应用程序中，我们将详细描述我们的极端 成功的临床研究设施和基础设施。我们还将强调我们有据可查的 优势包括患者增长和保留、高质量数据采集和输入、快速提升 启动新的试验、方案遵守情况、分析和出版效率以及协作成功 NICHD MFMU 网络中的协议开发和实施，该网络似乎是一个模型 拟议的新网络是基于该网络的。我们相信我们对这个项目的热情和承诺 将会很明显，我们相信我们的资格将非常有竞争力。